Sumitomo Mitsui DS Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Sumitomo Mitsui DS Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.97M	Buy	117,183 +106	+0.1%	+$3.53K	0.03%	392
2026 Q1	$3.53M	Hold	117,077	–	–	0.03%	398
2025 Q4	$3.65M	Hold	117,077	–	–	0.03%	383
2025 Q3	$2.36M	Sell	117,077 -179	-0.2%	-$3.14K	0.02%	473
2025 Q2	$1.97M	Hold	117,256	–	–	0.02%	508
2025 Q1	$1.8M	Buy	117,256 +11,912	+11%	+$213K	0.02%	511
2024 Q4	$2.32M	Buy	105,344 +332	+0.3%	+$6.04K	0.02%	451
2024 Q3	$1.89M	Sell	105,012 -163	-0.2%	-$2.85K	0.02%	493
2024 Q2	$1.71M	Buy	105,175 +9,903	+10%	+$153K	0.02%	482
2024 Q1	$1.34M	Buy	95,272 +10,087	+12%	+$127K	0.02%	537
2023 Q4	$889K	Sell	85,185 -337	-0.4%	-$3.15K	0.01%	635
2023 Q3	$872K	Buy	85,522 +290	+0.3%	+$2.7K	0.01%	589
2023 Q2	$642K	Sell	85,232 -489	-0.6%	-$3.96K	0.01%	646
2023 Q1	$759K	Buy	85,721 +8,341	+11%	+$82.5K	0.01%	602
2022 Q4	$706K	Hold	77,380	–	–	0.01%	591
2022 Q3	$624K	Buy	77,380 +8,305	+12%	+$73.4K	0.01%	591
2022 Q2	$519K	Buy	69,075 +14,597	+27%	+$127K	0.01%	620
2022 Q1	$512K	Sell	54,478 -12,606	-19%	-$105K	0.01%	656
2021 Q4	$537K	Buy	67,084 +9,782	+17%	+$88.3K	0.01%	658
2021 Q3	$558K	Sell	57,302 -440	-0.8%	-$4.12K	0.01%	640
2021 Q2	$571K	Sell	57,742 -4,689	-8%	-$49.6K	0.01%	650
2021 Q1	$720K	Buy	62,431 +6,873	+12%	+$78.8K	0.02%	564
2020 Q4	$536K	Sell	55,558 -2,747	-5%	-$26.3K	0.02%	600
2020 Q3	$525K	Sell	58,305 -148	-0.3%	-$1.57K	0.02%	564
2020 Q2	$720K	Sell	58,453 -5,275	-8%	-$59.7K	0.02%	476
2020 Q1	$572K	Buy	63,728 +2,938	+5%	+$30.1K	0.02%	469
2019 Q4	$595K	Buy	60,790 +4,252	+8%	+$38K	0.02%	563
2019 Q3	$388K	Buy	56,538 +460	+0.8%	+$3.52K	0.01%	599
2019 Q2	$517K	Sell	56,078 -5,672	-9%	-$68.4K	0.02%	548
2019 Q1	$968K	Buy	61,750 +5,707	+10%	+$101K	0.02%	526
2018 Q4	$864K	Sell	56,043 -4,217	-7%	-$86.5K	0.02%	498
2018 Q3	$1.3M	Sell	60,260 -1,187	-2%	-$27.6K	0.02%	462
2018 Q2	$1.49M	Buy	61,447 +4,310	+8%	+$87.9K	0.02%	419
2018 Q1	$976K	Sell	57,137 -1,880	-3%	-$36.7K	0.01%	523
2017 Q4	$1.12M	Sell	59,017 -5,994	-9%	-$90.2K	0.02%	488
2017 Q3	$1.14M	Sell	65,011 -3,387	-5%	-$76.2K	0.02%	441
2017 Q2	$2.27M	Sell	68,398 -881	-1%	-$27.3K	0.04%	321
2017 Q1	$2.22M	Buy	69,279 +7,021	+11%	+$240K	0.04%	326
2016 Q4	$2.26M	Buy	62,258 +37,017	+147%	+$1.48M	0.04%	297
2016 Q3	$1.16M	Sell	25,241 -4,282	-15%	-$223K	0.03%	400
2016 Q2	$1.48M	Buy	29,523 +7,507	+34%	+$400K	0.05%	319
2016 Q1	$1.18M	Buy	+22,016	New	+$1.29M	0.04%	360

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management's TEVA Position: Q2 2026 in Review

Sumitomo Mitsui DS Asset Management increased its Teva Pharmaceuticals (TEVA) stake by 0.09% in Q2 2026, buying an estimated $3.53K and bringing the position to 117,183 shares worth $3.97M. The position accounts for 0.03% of the portfolio, ranked #392.

Sumitomo Mitsui DS Asset Management first reported a position in TEVA in Q1 2016 and has held it in 42 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Sumitomo Mitsui DS Asset Management held 117,183 shares of Teva Pharmaceuticals worth $3.97M as of Q2 2026.
Sumitomo Mitsui DS Asset Management bought 106 Teva Pharmaceuticals shares in Q2 2026, an estimated $3.53K.
Teva Pharmaceuticals made up 0.03% of Sumitomo Mitsui DS Asset Management's portfolio in Q2 2026, its #392 holding.
Sumitomo Mitsui DS Asset Management first reported a position in Teva Pharmaceuticals in Q1 2016 and has held it in 42 quarters since.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q2 2026, filed 22 Jul 2026.